Beltroni Bio operates a balanced, hybrid therapeutic model—coupling an in-house de novo discovery platform with an internally owned pipeline of synthetic mini-protein agonists engineered for dermal barrier restoration, re-epithelialization, and cellular rejuvenation.
The Dual-Engine Framework
A proprietary de novo discovery platform driving an internally owned pipeline of skin-regenerative mini-protein therapeutics.
Generative structural modeling, interface hotspot design, and 500ns explicit-solvent molecular dynamics filtering allow target candidate generation and developability gating in weeks.
Commercial valuation is anchored directly in internally owned therapeutic candidates advancing through analytical binding validation (SPR/BLI), in vitro signaling, and localized delivery.
Lead Regenerative Program
Focused de novo lead diversity cohort
| Program ID | Target & Mechanism | Primary Indication | Modality | Development Stage |
|---|---|---|---|---|
| LEAD ASSET BB-DERM-01 | EGFR Domain III Non-oncogenic agonist mimetic (p-ERK/p-Akt) | Dermal Barrier Repair, Longevity & Re-epithelialization | De Novo Helical Mini-Protein (<80 aa) | Cell-Free Kinetic Gating (SPR/BLI) |
Deformable Nanocarrier Vehicle
Systemic capillary uptake is avoided and stratum corneum permeability is unlocked via an advanced elastic transfersome formulation engineered specifically for mini-protein payloads.